Massachusetts General Hospital

Boston, Massachusetts
Director of Thoracic Oncology and Attending Physician, Massachusetts General Hospital
Associate Professor Medicine, Harvard Medical School

Research

Dr. Alice Shaw’s research aims to provide viable treatments for lung cancer patients whose tumors have become resistant to their current drug therapy. With NFCR support since 2014, she seeks to develop new treatments for patients with anaplastic lymphoma kinase (ALK) mutations in non-small cell lung cancer. While only 5% of lung cancer patients are diagnosed with ALK-positive lung cancer (or ALK+ lung cancer), the ALK mutation leads to a high rate of cancer growth and spread to other parts of the body. Dr. Shaw was the lead investigator in the global registration studies for two drugs, which led to their FDA approval for advanced ALK+ lung cancer. These therapies have dramatically improved the outlook for patients, but, eventually, almost all patients will develop resistance.

By using multiple research models, Dr. Shaw and her team quickly identified new drug combinations for lung cancer patients who have developed resistance to their current therapy. Dr. Shaw demonstrated a marked regression of ALK+ lung cancer tumors in mice when treated with a combination of FDA-approved ALK+ lung cancer agents and inhibitors of SHP2 — a cancer gene that regulates cancer cell survival and growth and suppresses an immune system protein. In 2019, a first-in-human clinical trial led by Dr. Shaw began with this combination therapy. Hope is on the horizon with this new combination therapy for ALK+ lung cancer patients who have become resistant to standard targeted therapies.

Bio

Alice T. Shaw, M.D., Ph.D., received her B.A. in biochemistry at Harvard University and her M.D. and Ph.D. degrees from Harvard Medical School (where she is currently an Associate Professor). She then completed her residency at Massachusetts General Hospital and her postdoctoral work at Massachusetts Institute of Technology. Dr. Shaw was also a fellow at Massachusetts General Hospital and is currently the Director of Thoracic Oncology and an Attending Physician there.

In addition to her funding from NFCR, Dr. Shaw has been awarded other research grants throughout her career, including from the Damon Runyon Cancer Research Foundation, the Burroughs Welcome Fund, the V Foundation for Cancer Research, Uniting Against Lung Cancer and the National Institutes of Health.

Related Content

Research Highlight: Preventing Breast Cancer Brain Metastasis

National Foundation for Cancer Research funded researcher Dr. Daniel A Haber recently unearthed an exciting discovery that may add years to the lives of late-stage breast cancer patients. Dr. Haber is fascinated by understanding drug resistance on a deeper level by studying individual tumor cells in patients’ blood. In December 2020, Dr. Haber and his team shared their exciting findings on how brain metastasis, or the spread of cancer to the brain, may be prevented. Brain metastases occur in about 10% of all patients with cancer and in as many as a third of women with advanced metastatic breast cancer. Though experts have made great strides in suppressing the spread of cancer, there is still little known about the cellular pathways that enable cancer cells to selectively grow in the brain; that is, until Dr. Haber and his research team identified a signaling pathway which appeared significantly more active in brain metastases from breast cancer. “We were looking for what properties of some breast cancer cells made it possible for the cells to grow in the brain, which is a rare but often deadly complication of breast cancer,” Dr. Haber explained. “We weren’t sure what we would find. In a way that’s what makes the discovery process so exciting.” The research commenced approximately 10 years ago while investigating circulating tumor cells (CTCs). As their research progressed, the team homed in on a specific signaling pathway named HIF1A. Using cells from women with breast cancer, the team observed how these cells acted in animal models. It was discovered that if HIF1A was suppressed, the rate of proliferation (or rapid growth) was reduced. Simply put, blocking the HIF1A signaling pathway could reduce the rate of brain metastasis or even prevent it all together. “HIF1A is not specific to brain metastasis, since it’s a very broadly activated pathway in many cancers,” Dr. Haber began. “However, it appears to be more active in brain metastases from breast cancer than in primary breast cancers, and that may help explain what makes these metastases to the brain so unique and so difficult to treat.” The pathway identified in this research is already well known in the cancer world, however its special relevance to the brain was not known until now. Theoretically, a drug could be developed to suppress HIF1A and, in turn, prevent the spread of cancer. While a very promising discovery, Dr. Haber explains that there is far more work to be done. “There are a few HIF1A suppressing drugs now being tested in clinical trials for other indications,” Dr. Haber said, “However, we would have to expand this to multiple different models and systems before we could contemplate an intervention.” In regard to the length of time it takes to have a discovery such as this transitioned to mainstream treatment, Dr. Haber explains that it “depends on the discovery, its potential applications and some ‘luck’.” While the process from discovery to clinical treatment is getting faster all the time, it is likely going to take five to ten years before this finding is implemented into treatment. As for Dr. Haber, he has already planned plenty of work […]

Lung Cancer Awareness Month: Wildfires and Cancer

It’s already November and the dystopian year of 2020 has hardly been mundane. The year began with Australia ablaze, sending the world into a panic about the wellbeing of Australians and their notorious animals. As the year continued, health and wellbeing remained a priority for people around the world. Now, as the west coast is affected by disastrous wildfires, questions of health begin to arise once again. What’s the risk? Many people affected by the wildfires have expressed concerns about the long-term impacts the smoke may have on their health and how they can protect themselves and their family. The smoke from wildfires may have long-term health effects, but healthcare professionals advise that it is actually particles within the smoke that cause the biggest threat. Most smoke is filled with ash and debris, which can be harmful to ones’ health. Wildfire smoke, however, is particularly dangerous as the debris comes from a variety of burnt material, including appliances, home structures, and vehicles. Because there is such a large variety of burnt material, it is difficult to know exactly what is being inhaled, and therefore, how much of a cancer risk it may pose. Researchers have been curious about the cancerous effects of wildfire smoke on proximate citizens, but there is limited data available regarding length of exposure. Most published studies that have identified a link between wildfire smoke and an increased lung cancer risk have involved firefighters. These studies suggest that there is, in fact, a correlation between wildfire smoke and cancer; however the majority of the participants endured prolonged exposure. More data is required to determine the correlation of cancer risk with short-term exposure. How can I protect myself? As researchers continue to determine the risk wildfire smoke bears, the National Foundation for Cancer Research recommends taking precautions when exposed to wildfire smoke. Breathing in the ash and debris may pose a cancer risk, but it also has been linked to heart disease, COPD, and other respiratory conditions. To protect oneself, the US Centers for Disease Control and Prevention (CDC) suggests wearing a heavy-duty mask called a respirator when outdoors near smoke for an extended period of time. These masks are more protective than paper dust masks, which look like surgical masks, as they can trap smaller particles common in wildfire smoke. Staying inside can be a safe option if the air quality is low but the fires don’t present immediate danger to the area. When staying inside, it is important to keep doors and windows closed and secure and to run an air conditioner with the fresh air intake closed. Clean air conditioner filters will also help clear any debris or particles that may be in the air. It is also advised that families avoid vacuuming as it can redistribute settled particles into the air. For cancer patients or people who already have asthma or another lung disease, it is important to speak to a doctor to develop an action plan. Having an action plan ready, including an emergency contact, list of medications, and evacuation plan, can save time and help one’s family think quickly and clearly in […]

Small Cell Lung Cancer vs. Non-small Cell Lung Cancer: What’s the Difference?

From a distance, lung cancer may seem straightforward and cut-and-dried. The name itself sparks an immediate mental image of the balloon-like organ located in the chest cavity. It’s common knowledge that tobacco smoke is the leading cause of lung cancer, and that it is amongst the most common type of cancer. While these are great facts for the public to know offhand, there is actually quite a bit more information about lung cancer that is less commonly known. Small Cell Lung Cancer vs Non-Small Cell Lung Cancer Lung cancer diagnoses are broken down into two main groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC often starts in the bronchi, or the airways that lead from the trachea into the lungs and then branch off into progressively smaller structures. After affecting the bronchi, SCLC quickly grows and spread to other parts of the body, including the lymph nodes. This type of lung cancer represents fewer than 20% of lung cancers and is typically caused by tobacco smoking. SCLC itself is broken down into another two categories: small cell carcinoma and combined small cell carcinoma. These two categories are used to distinguish the small cells when viewed under a microscope. Small cell carcinoma is the most common type of SCLC and looks flat under a microscope, much like oats. Combined small cell carcinoma refers to a tumor made up of small cell carcinoma cells and a small number of non-small cell lung cancer cells. NSCLC accounts for nearly nine out of every 10 diagnoses and typically grows at a slower rate than SCLC. This type of lung cancer often develops slowly and causes few or no symptoms until it has advanced. There are three main types of NSCLC: adenocarcinoma of the lung, squamous cell, and large-cell undifferentiated carcinoma. Adenocarcinoma is the most common form of lung cancer, accounting for 30% of all cases overall and about 40% of all non-small cell lung cancer occurrences. This type of cancer is also found in other common cancers, including breast cancer and prostate cancer.  In NSCLC, it is found in the outer region of the lung, in glands that secrete mucus. Squamous cell lung cancer is responsible for about 30% of all non-small cell lung cancers and is generally linked to smoking. This type of cancer begins in the center of the lung. Large-cell undifferentiated carcinoma lung cancer accounts for approximately 10-15% of all NSCLC diagnoses. It can begin in any part of the lung and is known to grow and spread quickly. How Does Treatment Differ? Like most cancers, the treatment options are dependent on the stage the disease. The pace of treatment for SCLC is generally faster than NSCLC due to the tumors’ ability to quickly spread. NSCLC is less aggressive; however, it is typically identified at a later stage. In fact, only an approximate 25% of NSCLC patients are diagnosed at stage 1 or 2. For the minority who are diagnosed at stage 1 or 2, surgery to remove the tumor is often an option. Patients in the later stages are typically treated with chemotherapy and radiation. The treatment […]